Phase 3 T-cell Lymphoma Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 3
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Maintenance Treatment of Peripheral T-cell Lymphoma
Fudan University136 enrolled1 locationNCT07300514
Recruiting
Phase 3
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
T-cell Lymphoma
Peking Union Medical College Hospital107 enrolled1 locationNCT05075460
Recruiting
Phase 3
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Newly Diagnosed Peripheral T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University104 enrolled1 locationNCT05931263